Topics
Glioblastoma | Treatment | Targeted therapy | Pembrolizumab
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Pembrolizumab
Bagley SJ, Binder ZA, Lamrani L,
Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA,
Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W,
Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan
S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K,
Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon
JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated
peripheral infusions of anti-EGFRvIII CAR T cells in combination
with pembrolizumab show no efficacy in glioblastoma: a phase 1
trial.
Nat
Cancer. 2024 Jan
12. doi:
10.1038/s43018-023-00709-6. PMID:
38216766. Interventional study˰ ˍ
Yuen CA, Bao S, Pekmezci M, Mo F, Kong XT.
Pembrolizumab
in an HIV-infected patient with glioblastoma.
Immunotherapy.
2024 Jun 18:1-9. doi:
10.1080/1750743X.2024.2362566. PMID:
38889068. Case
report˰ ˍ